Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan.
Abatacept
Dickkopf-1
Musculoskeletal ultrasound
Osteoprotegerin
Power Doppler
Rheumatoid arthritis
Sclerostin
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
received:
25
08
2020
accepted:
24
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
4
6
2021
Statut:
epublish
Résumé
To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients' clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. 'Power Doppler (PD) responder' was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23-0.91, p = 0.043) was an independent predictor of PD responder status. Serum levels of bone biomarkers may be useful for predicting RA patients' therapeutic responses to abatacept. Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept.
METHODS
METHODS
We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients' clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. 'Power Doppler (PD) responder' was defined as a patient whose Δtotal PD score over 6 months was greater than the median change.
RESULTS
RESULTS
Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23-0.91, p = 0.043) was an independent predictor of PD responder status.
CONCLUSION
CONCLUSIONS
Serum levels of bone biomarkers may be useful for predicting RA patients' therapeutic responses to abatacept.
TRIAL REGISTRATION
BACKGROUND
Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657.
Identifiants
pubmed: 34074293
doi: 10.1186/s12891-021-04392-5
pii: 10.1186/s12891-021-04392-5
pmc: PMC8171043
doi:
Substances chimiques
Antirheumatic Agents
0
Biomarkers
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
506Subventions
Organisme : Bristol-Myers Squibb Canada
ID : N/A
Organisme : Ono Pharmaceutical
ID : N/A
Références
Rheumatology (Oxford). 2011 May;50(5):962-5
pubmed: 21186172
RMD Open. 2018 Dec 4;4(2):e000813
pubmed: 30622737
Ann Rheum Dis. 2006 Nov;65(11):1495-9
pubmed: 16606653
Ann Rheum Dis. 2010 Sep;69(9):1623-8
pubmed: 20525836
RMD Open. 2016 May 05;2(1):e000237
pubmed: 27175297
Scand J Rheumatol. 2020 Jan;49(1):13-17
pubmed: 31402744
Arthritis Rheum. 2008 Oct;58(10):2936-48
pubmed: 18821703
Ann N Y Acad Sci. 2018 Mar;1415(1):21-33
pubmed: 29500936
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
Ann Rheum Dis. 2017 Jan;76(1):7-8
pubmed: 27941072
Int Immunopharmacol. 2019 Feb;67:487-489
pubmed: 30599401
Int J Rheum Dis. 2014 Jan;17(1):50-6
pubmed: 24472267
Arthritis Care Res (Hoboken). 2018 Dec;70(12):1719-1726
pubmed: 29481732
Drug Discov Ther. 2019;13(1):22-27
pubmed: 30880318
Mediators Inflamm. 2014;2014:484280
pubmed: 24839355
J Rheumatol. 2013 May;40(5):653-62
pubmed: 23457381
Arthritis Rheum. 2008 Oct;58(10):2958-67
pubmed: 18821687
Clin Exp Rheumatol. 2011 Nov-Dec;29(6):921-5
pubmed: 22032557
Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
Clin Exp Immunol. 2018 Oct;194(1):1-8
pubmed: 30022480
Arthritis Rheumatol. 2014 Apr;66(4):990-9
pubmed: 24757150
Autoimmun Rev. 2017 Mar;16(3):313-320
pubmed: 28159704
Int J Mol Sci. 2019 Nov 07;20(22):
pubmed: 31703281
Ann Rheum Dis. 2013 Jun;72(6):804-14
pubmed: 23520036
Arthritis Res Ther. 2003;5(5):239-45
pubmed: 12932284
Ann Rheum Dis. 2008 Mar;67(3):353-7
pubmed: 17644538
Ann Rheum Dis. 2011 Oct;70(10):1826-30
pubmed: 21893583
Rheumatology (Oxford). 2004 Dec;43(12):1480-3
pubmed: 15353607
Arthritis Res. 2002;4 Suppl 3:S81-90
pubmed: 12110126
J Rheumatol. 2011 May;38(5):821-7
pubmed: 21362762
Adv Clin Exp Med. 2013 Mar-Apr;22(2):193-202
pubmed: 23709375
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Ann N Y Acad Sci. 1995 Apr 21;760:223-41
pubmed: 7785896
Arthritis Rheum. 2010 Jan;62(1):33-43
pubmed: 20039425
Ann Rheum Dis. 2011 Nov;70(11):1949-56
pubmed: 21821865
Med Sci Monit. 2020 Jan 30;26:e919159
pubmed: 31996665
Ann Rheum Dis. 2014 Jan;73(1):86-94
pubmed: 23962455
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Sci Transl Med. 2014 May 7;6(235):235ra60
pubmed: 24807557
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arthritis Rheum. 2002 Jun;46(6):1470-9
pubmed: 12115176
Nat Med. 2007 Feb;13(2):156-63
pubmed: 17237793
Ann Rheum Dis. 2015 Jan;74(1):19-26
pubmed: 25367713
Immunol Med. 2020 Sep;43(3):115-120
pubmed: 32393150
Joint Bone Spine. 2015 Mar;82(2):109-15
pubmed: 25557658
Ann Rheum Dis. 2008 Nov;67(11):1603-9
pubmed: 18203760